Search clinical trials for: ABBV-066

Total 801 results

AbbVie

Terminated

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Psoriasis

United States, Canada, Japan
AbbVie
Genmab

No longer available

Expanded Access to Epcoritamab

Lymphoma
AbbVie

Completed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Pancreatic Cancer

United States, Australia, Israel, Korea, Republic of, Puerto Rico, Spain
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Israel, Japan, Australia, Spain, Germany
AbbVie

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States, Israel, Japan, Korea, Republic of
AbbVie
Infinity Pharmaceuticals, Inc.

Completed

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Lymphoma

Japan
Genmab
AbbVie

Recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Non-hodgkin Lymphoma

United States, Australia, France, Israel, Korea, Republic of, Spain, Taiwan, Japan, Italy, Belgium, Germany, Canada, Turkey, Czechia
AbbVie

Active, not recruiting

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Australia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Taiwan
Calico Life Sciences LLC

Available

Expanded Access to ABBV-CLS-484

Advanced Solid Tumor Cancer
Calico Life Sciences LLC
AbbVie

Active, not recruiting

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis | ALS

United States, Canada
Morphotek
SCRI Development Innovations, LLC

Completed

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Adenocarcinoma | Breast Cancer | Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Pancreatic Cancer

United States
AbbVie

Completed

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Undifferentiated Pleomorphic Sarcoma | Carcinoma of the Breast

United States, France, Spain
AbbVie

Withdrawn

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome (SS)

Netherlands
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma

United States, Israel, Japan, Puerto Rico
AbbVie

Terminated

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Glioblastoma Multiforme | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Colorectal Carcinoma

United States, Spain
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Alzheimer's Disease

United States, Australia, Belgium, Canada, Denmark, Finland, Italy, Netherlands, New Zealand, Spain, Sweden
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Germany, Hungary, Israel, Netherlands, Poland, Puerto Rico
AbbVie

Active, not recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)

United States, Australia, France, Israel, Spain, Taiwan
AbbVie

Completed

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

Healthy Volunteer

United States
AbbVie

Completed

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Advanced Solid Tumors Cancer

United States, Australia, Israel
AbbVie

Not yet recruiting

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers

Healthy Volunteers
AbbVie

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

HIV Infection | HIV-1 | Human Immunodeficiency Virus (HIV)

United States, Australia, Canada, Puerto Rico
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis

United States, Canada, Germany, Israel, Poland
Biocad

Completed

Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers

Healthy

Russian Federation
AbbVie

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion

Immunoglobulin Light Chain (AL) Amyloidosis

Japan, United States
AbbVie

Completed

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

Dry Eye Syndrome

United States
AbbVie

Completed

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration

Healthy Volunteer

United States
AbbVie

Completed

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Ulcerative Colitis (UC)

United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
Southwest Oncology Group

Completed

Lung-MAP S1400K: c-MET Positive

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC V7

United States
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Australia, Canada, Czechia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukraine
Stemcentrx

Terminated

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Ovarian Cancer

United States
AbbVie

Recruiting

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)

Hepatocellular Carcinoma

United States, Japan, Taiwan, Korea, Republic of, Spain, France, Italy
AbbVie

Completed

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

Parkinson's Disease

United States
AlaMab Therapeutics (Shanghai) Inc.

Recruiting

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

Acute Spinal Cord Injury

China
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Vaxon Biotech

Completed

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Solid Tumor

Greece
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
AbbVie

Completed

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Brazil
AbbVie
Idera Pharmaceuticals, Inc.

Completed

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Advanced Solid Tumors Cancer

United States, France, Germany, Israel, Netherlands, Spain
AbbVie

Completed

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Parkinson's Disease (PD)

United States
Butler Hospital
Brown University

Completed

Engaging HIV Patients in Primary Care by Promoting Acceptance (HIV Engage)

HIV

United States
AbbVie

Active, not recruiting

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
AbbVie

Completed

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia, Austria, Belgium, Canada, Finland, France, Japan, Spain, Taiwan
University of California, Davis
University of Michigan; University of California, Riverside; Lahore University...

Terminated

Impact Evaluation of Super Abbu: A Speech Based MNCH Platform in Pakistan

Maternal and Child Health

Pakistan
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
AbbVie

No longer available

Expanded Access to ABBV-8E12

Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Merit E. Cudkowicz, MD
Massachusetts General Hospital

Active, not recruiting

HEALEY ALS Platform Trial - Master Protocol

Amyotrophic Lateral Sclerosis

United States
AbbVie

Completed

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Cancer | Breast Cancer | Small Cell Lung Cancer | Multiple Myeloma | Non-Small Cell Lung Cancer | Prostate Cancer | Non-Hodgkins Lymphoma | Acute Myeloid Leukemia (AML)

United States

3

Subscribe